// App-Quantinova.ai

4065 : Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).

Researchers

Presenter

  • Karina Kulangara

Principal Investigators

  • Lindsay Guerrero

  • Alex Posch

  • Scott Boyer

  • Debra Ann Hanks

  • Josette Carnahan

  • Jiangdian Wang

  • Jared Lunceford

  • Mary Savage

  • Matthew John Marton

  • Scott K. Pruitt

  • Jonathan Wes Juco

  • Kenneth Emancipator

Medical Centers

  • Dako North America, Agilent Technologies, Carpinteria, CA

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02335411

  • NCT02628067

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved